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Introduction
The cerebrospinal fluid (CSF) compartments are increasingly recognized for their vital role in bridging 
the CNS with the peripheral immune system. Immune cells, including central memory T cells, circulate 
throughout the CSF in the ventricles and subarachnoid spaces to surveil the CNS parenchyma, after cross-
ing the blood-CSF barrier (BCSFB) in the choroid plexus (1). Together with the blood-brain barrier (BBB), 
the BCSFB tightly regulates the entry of  cells and solutes into the CNS. When these barriers and other 
regulatory mechanisms break down, immune cells enter the CNS and may initiate neuroinflammatory 
diseases such as multiple sclerosis (MS) (2). In MS, pathological immune cells trigger demyelination and 
neurodegeneration, ultimately causing clinical disability.
MRI is an indispensable tool in diagnosing MS and monitoring disease progression (3–6). Disruptions 
of  the BBB can be revealed by MRI using gadolinium-based contrast agents (GBCA). Contrast-enhancing 
lesions (CEL) indicate recent inflammatory activity, predominantly seen during the relapsing-remitting 
The brain ventricles are part of the fluid compartments bridging the CNS with the periphery. Using 
MRI, we previously observed a pronounced increase in ventricle volume (VV) in the experimental 
autoimmune encephalomyelitis (EAE) model of multiple sclerosis (MS). Here, we examined VV 
changes in EAE and MS patients in longitudinal studies with frequent serial MRI scans. EAE mice 
underwent serial MRI for up to 2 months, with gadolinium contrast as a proxy of inflammation, 
confirmed by histopathology. We performed a time-series analysis of clinical and MRI data 
from a prior clinical trial in which RRMS patients underwent monthly MRI scans over 1 year. 
VV increased dramatically during preonset EAE, resolving upon clinical remission. VV changes 
coincided with blood-brain barrier disruption and inflammation. VV was normal at the termination 
of the experiment, when mice were still symptomatic. The majority of relapsing-remitting MS 
(RRMS) patients showed dynamic VV fluctuations. Patients with contracting VV had lower disease 
severity and a shorter duration. These changes demonstrate that VV does not necessarily expand 
irreversibly in MS but, over short time scales, can expand and contract. Frequent monitoring of VV 
in patients will be essential to disentangle the disease-related processes driving short-term VV 
oscillations from persistent expansion resulting from atrophy.
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(RR) disease phases. Contrast enhancement is currently the only MRI feature to assess the lesion acuity 
at the time of  first assessment (7, 8), but increasing concerns regarding potential long-term deposition of  
gadolinium in the brain could potentially restrict the application of  this important diagnostic tool (9–12). 
Improvements in MRI technology and a better understanding of  key aspects of  MS pathology promise to 
better identify changes in the CNS of  MS patients and to provide clinicians with a better guide to enhance 
the accuracy and speed of  an MS diagnosis (5).
The experimental autoimmune encephalomyelitis (EAE) animal model of neuroinflammation resembles 
several aspects of MS and has proven invaluable for gaining insight into its pathological processes and identifi-
cation of new treatment strategies (13). Studies in the EAE model afford the possibility to directly relate MRI 
findings with histopathological correlates and to study the phase of disease before clinical onset — investigations 
that are challenging to perform in patients. We showed, using high-resolution microscopic MRI, that inflamma-
tory lesions could be detected in the cerebellum, cortex, and periventricular regions early in disease, before the 
onset of clinical EAE signs (14). During this preonset phase of EAE, we observed a marked and reproducible 
enlargement of the brain ventricles (15). This was surprising, since profound neurodegeneration at this very early 
stage of disease before the emergence of clinical signs is unlikely to be the explanation for the expansion.
Cerebral ventricle enlargement is commonly linked to neurodegeneration and brain atrophy. While this 
occurs during the course of  normal aging, shrinkage of  the cortex and expansion of  the ventricles proceeds 
more rapidly in MS patients (16–21), especially during the secondary progressive phase of  MS (SPMS), in 
which neurodegenerative processes dominate. Nevertheless, neurodegeneration — of  the deep gray matter, 
in particular — can also occur from the earliest stages of  brain inflammatory disease (22, 23), and it is 
essential that aspects of  disease relating to inflammation are disentangled from those relating to neurode-
generation. For this, it is crucial that noninvasive investigations are carried out at frequent time intervals in 
order to capture events that are likely to be overlooked in cross-sectional studies or longitudinal studies with 
long intervals between observations. Furthermore, correlations among multiple variables during the course 
of  disease should be carefully considered as a time series, to elucidate possible pathological relationships.
To detail fluctuations in the ventricles, the current study examined ventricle volume (VV) changes in 
both EAE mice and MS patients in longitudinal studies designed with frequent serial MRI scans. We used 
a time-series approach to study the relationship of  VV with other MRI and clinical variables relevant to the 
pathology. In EAE mice, we performed frequent MRI scans for up to 2 months in order to investigate how 
inflammatory processes may affect VV beyond the initial acute phase of  disease activity. To ascertain the 
clinical relevance of  VV fluctuations in MS, we undertook a retrospective exploratory analysis of  data from 
a prior clinical trial, in which patients with definite RRMS underwent monthly MRI scans over the course 
of  one year. This design afforded a higher time resolution than is typically used, while balancing the practi-
calities of  conducting clinical studies in MS patients. We used time-series analysis to explore how changes in 
VV over time relate to changes in other MRI and clinical parameters. In this study, we explored the potential 
of  brain ventricle size changes as a possible MRI biomarker that could serve as a proxy of  disease activity.
Results
VV changes dynamically during the course of  EAE. We performed frequent MRI of  EAE mice over a period 
of  2 months in order to investigate changes beyond the presymptomatic phase and the first disease peak 
and remission, typically examined in many EAE studies. During the initial disease phase, there was a pro-
nounced increase in VV that is clearly visible on anatomical MRIs (Figure 1A), confirming our previous 
observation (15). By  day 8 (d8) postimmunization (p.i.), the group mean increase in VV relative to baseline 
values was 130.8% ± 7.74% (mean ± SEM, P < 0.001, 1-way ANOVA) (Figure 1B). This was well beyond 
the range of  normal VV variation in healthy unmanipulated SJL mice, which we determined in our previous 
study (n = 6) to be plus or minus 6% (15). This increase peaked at 160.7% ± 10.25% and 157.5% ± 7.69% by 
d11 and d13 p.i. Four mice in the cohort showed VV increases greater than 200%.
The magnitude of  expansion began tapering at d15 p.i. (139.9% ± 6.68%), and mean VV eventually 
returned to baseline levels by d22 (Figure 1B). For n = 9 SJL mice, we continued MRI examinations every 
2–3 days, up to d64 p.i., in order to follow the VV changes downstream of  the initial disease phase. The 
mice showed a typical RR disease course, with clinical signs developing around d10 p.i., peaking at d14 p.i., 
and remitting by d20–d22 p.i. (Figure 1C).
The expansion and contraction in VV followed a similar course as the neurological signs. In the repre-
sentative case shown in Figure 1A, VV expansions can be seen at d13, d29, and d46 p.i., each followed by 
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Figure 1. Ventricle volume changes dynamically during the course of EAE. (A) T2-weighted horizontal MRI scans of a representative mouse brain show 
changes in ventricle size from baseline (day –2) to day 64 p.i. (B) Brain ventricle volume plotted as a percentage of baseline values (n = 35). By day 8 p.i., 
the mean volume was 130.8% ± 7.74% (± SEM) of the baseline volume (P < 0.001, ANOVA), well beyond the range of normal variation in healthy SJL mice of 
± 6%. Ventricle volume peaked at days 11–13 p.i. and returned to baseline levels by day 22 p.i. (C) Emergence and remission of EAE clinical signs coincided 
with the peak expansion and contraction of ventricle volume (mean ± SEM).
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VV contractions at d20, d34, and d64, respectively (Figure 1A). The timing of  VV normalization coincided 
with remission of  clinical signs, although there were differences in the kinetics among individual animals, 
especially at later time points. VV continued to change during the chronic stage of  disease, though gener-
ally, these fluctuations were less pronounced than the prominent changes observed during the initial acute 
disease phase. All animals that were monitored after the initial VV expansion showed contractions back to 
normal volumes — i.e., no animal displayed permanently enlarged ventricles. Importantly, at the end of  the 
experiment (d64), while most animals still exhibited a degree of  neurological disease severity (EAE score 
2.0 ± 1.75, median ± IQR), VVs had returned to normal baseline values.
Ventricle enlargement coincides with emergence of  gadolinium-enhancing lesions and precedes onset of  clinical 
signs of  EAE. To explore the relationship between VV changes and BBB breakdown during inflammation, 
we administered GBCA to EAE mice during the early acute phase of  disease. T1 mapping was performed 
to obtain an unbiased quantitative measurement of  the global changes in tissue relaxation caused by leak-
age of  the GBCA into the brain parenchyma. In order to make the quantification robust across the longi-
tudinal series of  scans, images from each time point were registered to the baseline image (2 days before 
immunization [d–2]), for each individual animal.
A typical pattern of  contrast enhancement — with diffuse lesions especially prominent in the cer-
ebellum, meninges, and periventricular regions — was observed already by d5 p.i. (Figure 2A). The 
change in brain T1 values after GBCA administration (ΔT1 = precontrast minus postcontrast mean val-
ues) was calculated for n = 16 mice, at time points ranging from baseline (d–2 p.i.) to d25 p.i. (Figure 2, 
B and C). Compared with baseline, the ΔT1 in the cerebellum was significantly increased at d8 and d11 
p.i. (592.9 ± 103.8 ms and 551.2 ± 71.4 ms, respectively, P = 0.0030, 1-way ANOVA) (Figure 2B). The 
ΔT1 in the whole brain (Figure 2C), was also significantly increased at d8 and d11 p.i. (373.1 ± 52.9 ms 
and 342.8 ± 43.2 ms, respectively, P = 0.0023, 1-way ANOVA).
Gadolinium enhancement was observed before the onset of  clinical signs (Figure 2D), although the 
timing of  this varied among animals. We compared the timing of  changes in ΔT1 with that of  VV and clin-
ical changes (Figure 2D). There was no significant difference in the time to show VV increases > 6% and 
the time to show the maximum change in ΔT1 (P = 0.2800, log-rank test) (Figure 2D). Both VV and ΔT1 
increases occurred significantly earlier than the onset of  EAE clinical signs (P = 0.0068 and P = 0.0005, 
respectively). The onset of  EAE clinical signs is often accompanied by a substantial reduction in body 
weight. Maximum body weight loss also occurred significantly later than both VV and ΔT1 changes (P = 
0.008 and P < 0.0001, respectively) (Figure 2D).
Early ventricle enlargement in EAE correlates with inflammation and minimal neurodegeneration. The macro-
scopic VV expansion observed by MRI could also be seen by gross examination of  histological sections 
(Figure 3). With histological staining, we could follow the emergence of  inflammatory cell infiltration in 
EAE brains (n = 19) up to d11 p.i. (Figure 3, A–U). Representative images of  H&E-stained sections show 
no apparent pathology before immunization (Figure 3, A–D) or at d3 p.i. (Figure 3, E–G). The first signs 
of  pathology were detected on d5 (Figure 3, H–J), as shown by the start of  meningeal infiltration of  mac-
rophage/myeloid cells (F4/80 staining) and accompanying gliosis (GFAP staining) (Figure 3I) and the 
appearance of  cerebellar lesions (Figure 3J). By d8 p.i., the inflammation was even more evident (Figure 3, 
K–M). This corresponds to the time point of  statistically significant increases in VV and GBCA enhance-
ment observed by MRI. At this time point, we observed pronounced meningeal inflammation and gliosis 
(Figure 3L), as well as T cell infiltration in the parenchyma, as shown by CD3 stains (Figure 3M). By d11 
p.i., the marked increase in volume of  the lateral, third, and fourth ventricles (Figure 3N) was accompanied 
by extensive histopathology, especially prominent in periventricular regions (Figure 3, O–Q) and cerebel-
lum (Figure 3, R and S), as well as brainstem and meninges (Figure 3, T and U).
Semiquantitative scoring of  the severity of  inflammation positively correlated with VV — i.e., mice 
with the largest increase of  VV showed greater burden of  histopathology (Spearman’s r = 0.7225, P = 
0.0023) (Figure 3V). The histopathology score also correlated with the ΔT1 of  the brain (Spearman’s r = 
0.7480, P = 0.0013) (Figure 3W).
Neurodegeneration is expected during the course of  EAE. We performed Fluoro-Jade (FJ) staining on 
serial sections from the same tissue samples shown in Figure 3 in order to determine to what extent this relat-
ed to the inflammatory pathology and VV enlargement. No FJ+ staining was seen in unimmunized animals 
(Figure 4, A and C) or at d3 p.i. FJ+ foci were seen infrequently on d5 p.i., became more readily apparent 
by d8 p.i., and were more frequently observed by d11, in cerebellum and the brainstem (Figure 4, B and D). 
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Although FJ+ foci always accompanied inflammatory lesions, only minimal FJ staining was observed in 
periventricular lesions. Quantification of  FJ staining intensity from whole brain sections illustrates a mod-
est yet increasing accumulation of  neurodegeneration during this early phase of  EAE (Figure 4E).
Dynamic changes in VVs in RRMS patients. The magnitude and timing of  the VV changes in the EAE 
model were compelling. Nevertheless, the validation that these findings in the animal had any translation-
al relevance for MS patients remained to be demonstrated. For this, we performed a time-series analysis 
(Figure 5) of  data from our previous clinical study (NCT00616187) (24), in which RRMS patients (n = 33) 
underwent 13 serial MRI examinations over 1 year (Figure 5). This was a baseline-to-treatment clinical 
study of  oral high-dose atorvastatin treatment for RRMS; all patients received atorvastatin, and 10 of  33 
patients also received IFN-β throughout the study. This study included both MRI (n = 8) as well as clinical 
(n = 4) parameters measured at each time point.
Considering the entire cohort of  33 patients, there was a small but significant increase in the median 
VV between baseline and the last time point at the conclusion of  the study: baseline volume = 33,500 mm3 
(27,028 – 39,468) (median ± IQR) versus 33,784 (27,953 – 41,185), resulting in an increase of  284 mm3, 
equivalent to an increase of  0.08406% (P = 0.0006, Wilcoxon’s signed rank test) (Figure 6A). However, 
plotting the VV changes over time, expressed as percent changes relative to the VV at baseline for each 
individual, revealed a highly heterogeneous picture. Some patients showed substantial volatility in VV over 
time (Figure 6B), while others showed minimal changes (Figure 6C). To distinguish among cases with 
varying VV volatility, we first determined the normally expected range of  intraindividual variation in VV in 
healthy individuals by making use of  data from a study that performed serial MRI of  healthy subjects over 
6 months (25), selecting time points to match the 1-month time intervals separating scans of  the MS cohort. 
We calculated the median VV for each time point (Figure 6D) and changes in VV relative to baseline for 
each healthy control (Figure 6E). From this data, we determined that the intraindividual variation in VV 
fluctuated by plus or minus 6% over time in healthy subjects (Figure 6E). This result was corroborated by 
analysis of  data from a second study that performed serial scans on healthy individuals (26).
In a large proportion of  MS patients (21 of  33, 64%), changes in VV exceeding the 6% threshold were 
observed within 1-month intervals. A subset of  patients (5 of  33, 15%) showed exclusively positive changes 
in VV over the duration of  the study — but no contractions. When this minority was excluded from the 
analysis, the remaining patients showed a small overall decrease in VV (33,000 [27,560 – 39,750] versus 
32798 [28,323 – 41,490], –0.00612% [baseline versus last time point, median ± IQR, P = 0.0098, Wilcox-
on’s]). A larger fraction of  patients, 24 of  33 (73%), showed VV contractions beyond the 6% threshold, 
which extended consecutively over a period of  at least 2 months, with no expansions in between. VV 
changes in this cohort were not a monotonic increase in volume throughout the study period. Based on this 
threshold, we segregated the patients into 2 groups, considering that a VV contraction event (beyond the 
level of  normal variation) would necessarily follow an expansion event and that such a contraction could 
exclude VV changes due to brain atrophy. One group (n = 24) was labeled as MS patients with contractions 
> 6% (Figure 6B), and the other group (n = 9) was labeled as noncontracting MS patients (Figure 6C). The 
range of  plus or minus 6% is depicted by a dotted line (Figure 6, B, C, and E). The whole MS patient cohort 
had significantly greater volatility in ventricle size, with the coefficient of  variation (CV) in VV of  3.235 ± 
0.234 versus that of  controls 1.887 ± 0.327 (mean ± SEM, P = 0.0065, 2-tailed Student’s t test) (Figure 6F).
Even within each patient group, there was a large variation in the magnitude of VV changes, as shown from 
the plot of relative VV changes for each individual patient during the study (Figure 7, lower panel). The max-
imum VV contraction for each patient (over 2 months) is depicted in the lollipop plot (Figure 7, upper panel).
Upon stratifying the patients, we investigated potential differences between the groups that could be 
relevant to MS. MS patients with VV contractions > 6% had significantly lower baseline expanded disability 
Figure 2. Ventricle enlargement coincides with gadolinium-enhancing lesions and precedes EAE clinical signs. (A) T1 map MRIs of a representa-
tive mouse brain show altered tissue relaxation due to blood-brain barrier disruption following administration of gadolinium-based contrast agent. 
Reduced tissue T1 (purple) is apparent in the meninges, cerebellum, and periventricular regions already by day 5 p.i. Note that the brain images have 
been registered to the baseline image for quantification; therefore, changes in ventricle volume are not apparent in these images. (B) Quantification 
of global changes in tissue T1 following gadolinium contrast administration were especially prominent in the cerebellum (n = 16). The ΔT1 (precon-
trast – postcontrast values) was significantly increased from baseline at days 8–11 p.i. (P = 0.0030, ANOVA). (C) The ΔT1 of the whole-brain was also 
significantly increased at days 8–11 p.i. (P = 0.0023, ANOVA). (D) Kaplan-Meier plots show that the time of onset of ventricle expansion and the time 
of maximal gadolinium enhancement significantly preceded the onset of EAE clinical signs (P = 0.0068 and P = 0.0005, respectively; log-rank test) 
and the time of maximal body weight loss (P = 0.008, P < 0.0001, respectively).
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Figure 3. Early ventricle enlargement in EAE correlates with inflammation. (A–G) Representative images of H&E-stained tissue sections show absence 
of pathology at baseline (A–D) and day 3 p.i. (E–G). Higher magnifications views show periventricular (B and F), meningeal (C), and cerebellar regions (D 
and G). (H–J) First signs of pathology were detected on day 5 p.i., as infiltration of macrophage/myeloid cells (F4/80+, red) and accompanying gliosis (GFAP, 
green) in meningeal areas (I) and inflammatory foci in cerebellar white matter (J). (K–M) By day 8 p.i., pronounced meningeal infiltration and gliosis was 
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status scale (EDSS) and median EDSS throughout the study period compared with patients with no VV 
contractions > 6% (P = 0.0221, P = 0.0063, respectively; Mann-Whitney U test) (Figure 8, A and B). Patients 
with contracting VV also had a significantly lower total disease duration time (P = 0.046, 2-tailed Student’s 
t test) (Figure 8C). There were no significant differences between contracting and noncontracting patients 
in the total burden of  CEL, T2, or black hole (BH) lesion volume over the course of  the study (P = 0.289, P 
= 0.592, P = 0.598, respectively; Mann-Whitney U test) (Figure 8, D–F). Contracting and noncontracting 
patients did not differ in terms of  age, sex, the proportion also receiving IFN-β therapy, or number of  acute 
relapses during the study period (P = 0.26, P = 0.748, P = 0.511, P = 0.582, respectively; 2-tailed Student’s 
t test, χ2 test for proportion with therapy). Patients did not show any significant loss of  total brain volume 
(BV) during the course of  the study, either when considering the entire cohort (P = 0.1167) or the contracting 
and noncontracting patients separately (P = 0.8750, P = 0.9770, respectively; 2-way ANOVA with Tukey’s 
post hoc test; Supplemental Figure 1; supplemental material available online with this article; https://doi.
org/10.1172/jci.insight.140040DS1). Even when comparing across all time points, we did not observe sig-
nificant changes in BV. There was, however, a significant negative correlation between VV and overall BV, 
considering the entire cohort, at selected time points (Supplemental Figure1 and Supplemental Table 2).
Time-series analysis of  VV changes in MS. Given the heterogeneity of  VV changes in the MS cohort, analysis 
of  group means can potentially obscure relationships between VV changes and other parameters that are 
relevant to MS pathology. To address whether significant temporal relationships exist between VV changes 
and changes in other MRI and clinical parameters, we used time-series analysis (a schematic outline of  the 
workflow is depicted in Figure 5). All clinical and MRI parameters (including VV measured from anatomical 
T1 and T2 images) acquired at each time point during the study were included in the analysis. Given the para-
metric nature of  the time-series analysis, ordinal variables such as EDSS were not included. We performed 
the time-series analysis on the subset of  24 MS patients who showed VV contractions above the 6% threshold.
We calculated the cross-correlation function (CCF) for each individual patient using VV as the X vari-
able and the other 8 MRI and 4 clinical parameters as Y variables. We considered only those significant 
cross-correlation coefficients that occurred within plus or minus 2 time lags (i.e., ±2 months) as reflecting 
a meaningful temporal relationship with VV changes (Figure 9A). The CCF analysis resulted in a total of  
101 cross-correlation coefficients with nominal P < 0.05. Upon FDR correction for multiple comparisons, 
25 significant coefficients were retained (Figure 9A). The significant cross-correlation coefficients were 
detected in 10 of  24 MS patients included in the analysis. These were distributed among all clinical param-
eters and most of  the MRI (7 of  8) parameters. All 5 time lags considered (0, ±1, and ±2 months) appeared 
among the significant cross-correlations.
Detection of  CEL is a major criterion for MS diagnosis. The CCF analysis was repeated using CEL 
volume as the X variable and the remaining 12 parameters (including VV) as Y variables (Figure 9B). 
This analysis yielded a total of  96 cross-correlations with nominal P < 0.05. This was reduced to 23 sig-
nificant cross-correlations following FDR correction for multiple comparisons (Figure 9B). Of  note, 9 of  
23 significant cross-correlations were correlations between CEL volume and CEL count, which was to be 
expected, and 14 of  23 were at 0 lags (i.e., the changes occurred at the same time as CEL volume changes).
As an additional comparison, we repeated the CCF analysis using the performance in the 9-hole 
peg test of  the dominant hand (hpt dom) as the X variable and comparing it with the other 12 param-
eters (including VV) as Y parameters (Figure 9C). This analysis yielded 73 cross-correlations with 
nominal P < 0.05; only 5 significant cross-correlations were retained following correction for multiple 
comparisons (Figure 9C).
Discussion
In this study, we demonstrate a pronounced enlargement of  the mouse brain ventricles of  up to 200%, 
before the onset of  clinical signs, during the first disease peak in EAE. We show that this enlargement 
resolves at the time of  clinical remission, strongly suggesting that it is not the result of  brain atrophy due 
present (L), along with T cell infiltration in the parenchyma (CD3+, green) (M). (N) At day 11 p.i., ventricular enlargement was grossly apparent from the 
whole brain tissue sections. (O–U) Extensive inflammation was seen throughout the brain, including periventricular regions (O, P, Q), cerebellum (R, S), 
and meningeal areas (T, U), along with gliosis (Q) and infiltration of F4/80 and CD3 positive cells (Q, S, U). (V and W) Semiquantitative scoring of histopa-
thology (n = 19) correlated positively with ventricle volume changes (V) and gadolinium enhancement as ΔT1 changes in whole brain (W) (Spearman’s r). 
Scale bars: A (whole brain images): 2 mm; B–D, F, and G: 500 μm; P–R: 200 μm; I and J, L and M, O, and S–U: 100 μm.
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Figure 4. Modest neurodegeneration detected by Fluoro-Jade staining during early EAE. (A and C) No evidence of Fluoro-Jade+ staining was seen 
in brain tissue sections from unimmunized control mice; representative images of cerebellum (A) and brainstem (C). (B and D) Fluoro-Jade+ foci 
(indicated with arrows) were observed in cerebellum (B) and brainstem (D) of mice at day 11 p.i. (Fluoro-Jade, green; DAPI, blue). The Fluoro-Jade+ 
foci consistently accompanied inflammatory foci (B and D). (E) Quantification of fluorescence intensity of the tissue section showed an increasing 
accumulation of Fluoro-Jade staining by day 11 p.i. (arbitrary units) (n = 15).
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to neurodegeneration. The VV continues to fluctuate during the disease course. This phenomenon has 
clinical relevance, as the majority of  RRMS patients in our cohort showed dynamic enlargement and 
contraction of  VV, beyond the range of  variation seen in healthy individuals. Those patients who showed 
the most volatility in VV appeared to be at an earlier stage of  disease; they had significantly lower base-
line and median EDSS throughout the study period, and they had a significantly shorter total disease 
duration compared with the patients who did not show contractions. Crucially, these results demonstrate 
that VV in RRMS patients does not only increase unidirectionally over time as a result of  atrophy, but in 
the majority of  cases, VV expands and contracts dynamically during the disease course. These short-term 
fluctuations occur at a time scale of  less than 1 year and are unlikely to be the result of  neurodegener-
ation exclusively. They suggest that other disease-related processes might be contributing factors. Close 
monitoring of  VV changes during disease could therefore offer further valuable insights.
A distinguishing feature of  this work is the relatively high time resolution of  the longitudinal stud-
ies. EAE mice were scanned every 2–3 days over a period of  64 days. EAE studies typically consider 
fewer time points during the disease course. Long intervals between observations can limit the detection 
of  potential changes that take place at shorter time scales, obscuring the complexities of  the underlying 
processes. Similarly, the clinical study we investigated for time-series analysis was originally designed 
to evaluate the efficacy of  atorvastatin in RRMS patients and included 13 monthly MRI investigations 
over a period of  1 year. These time intervals are shorter than those typically considered in clinical prac-
tice and offer the possibility to capture subtle changes that might otherwise remain unnoticed.
In our analysis, we considered changes at the individual patient level. When analyzing the MS patients 
as a group, we observed a small though significant increase in VV between the start and end of  the study, 
which is consistent with the conventional interpretation of  neurodegeneration and brain atrophy (27). How-
ever, there was no significant change in BV throughout the study, suggesting that subtle atrophy may be 
proceeding on a central rather than global level (28, 29). It is expected that VV will increase over time in the 
course of  normal aging, and it is indisputable that this is accelerated in MS (19, 21, 30, 31). When studying 
the VV in MS patients individually, we observed an oscillating behavior in the majority of  patients, with VV 
expansions and contractions. This suggested that, superimposed upon the long-term expansion of  VV result-
ing from neurodegeneration, other disease-related processes drive the short-term oscillations in VV. Another 
confounding process is the phenomenon of  pseudoatrophy (nontissue related BV reduction) that can occur 
following introduction of  antiinflammatory therapies (32–34) as a result of  accelerated water losses and 
Figure 5. Schematic for time-series analysis workflow. From the cohort of n = 33 RRMS patients, we performed the time-series analysis on the subset 
of n = 24 patients who showed contractions in ventricle volume greater than the ± 6% range of normal variation. Ventricle volumes were measured at 
13 monthly time points. At the same time points, an additional 8 MRI parameters and 4 clinical parameters were measured. This allowed each of these 
measures to be considered as a time series. Using the cross-correlation function, the cross-correlation coefficients between 2 time series can be calcu-
lated; significant coefficients indicate that events of one series precede (negative time lag) or follow (positive time lag) the events of another series. In 
the current study, we limited the consideration of significant cross-correlation coefficients to ± 2 time lags (i.e., ± 2 months). From n = 24 patients, n = 12 
variables, and n = 5 time lags (including the 0 time lag), a total of 1440 coefficients was calculated. From the coefficients with nominal P < 0.05, the FDR 
correction for multiple comparisons was applied, to yield the corrected significant cross-correlation coefficients, which were then displayed in the 3D plots.
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fluid shifts (35), as well as resolution of  immune cell infiltration. The patients in the clinical trial that we 
retrospectively investigated were treated with atorvastatin (and some also with IFN-β) but did not show any 
signs suggestive of  pseudoatrophy (24). During the relatively short duration of  our study (1 year), there was 
no significant reduction in BV in all cohorts. Aside from pseudoatrophy, some immunomodulatory agents 
(e.g., S1P agonists) appeared to slow down BV losses. In addition to reducing new MRI activity, 6 months 
of  treatment with fingolimod resulted in significantly lower BV losses compared with placebo control (36), 
suggesting neuroprotective mechanisms were operating, beyond the expected antiinflammatory activity. In 
parallel to monitoring BV changes, it would be interesting to follow changes in VV in S1P agonist–treated 
patients as a possible surrogate marker to differentiate antiinflammatory from neuroprotective activities. In 
such studies, a high frequency of  MRI scans, as performed in the presently investigated clinical study, would 
facilitate the disentanglement of  immunomodulatory-induced reductions in transient VV fluctuations from 
neuroprotective-induced reductions in BV losses that occur at different time scales. Distinguishing short-
term processes from long-term VV and BV changes is vital, especially since the rate of  VV expansion was 
shown to predict disease progression more strongly than the rate of  whole brain atrophy (20).
The dynamics of  CSF flow through the brain, and how this is altered under pathological conditions, 
is receiving increased attention in light of  the recognition of  the glymphatic system within the brain (37). 
CSF flows from the choroid plexus through the ventricular system and enters the brain parenchyma via the 
perivascular spaces along arteries, where it mixes with interstitial fluid (38). The CSF exits the brain along 
the perivenous spaces to the cervical lymphatics, the arachnoid granulations, and the meningeal lymphat-
ics (39, 40). Immune cell accumulation in the perivascular space could interfere with normal glymphatic 
processes, and meningeal inflammation could disrupt clearance of  the CSF. We observed that meningeal 
inflammation was extensive in EAE brains by d11 p.i. and could already be detected as early as d5 p.i. This 
is consistent with other reports that meningeal inflammation preceded inflammation in the parenchyma 
(41). A recent report described GBCA enhancements in the leptomeninges in myelin oligodendrocyte glyco-
protein–immunized (MOG-immunized) C57BL/6J EAE mice, and these were especially prominent during 
the initial disease peak (42). In proteolipid protein–immunized (PLP-immunized) SJL/J EAE mice, we also 
observed GBCA leakage early during disease, as shown by reduced T1 values, particularly in leptomeningeal 
Figure 6. Relapsing-remitting MS patients show dynamic changes in ventricle volumes. (A) Over the course of 1 year, the cohort of MS patients showed 
a small but significant increase in ventricle volume of +284 mm, equivalent to +0.08406% (median ± IQR, P = 0.0006, Wilcoxon signed rank test, n = 33). 
(B and C) Plotting the values for individual patients showed a heterogeneous picture, with some individuals showing high variability in ventricle volume (B) 
and others showing lower variability (C). (D) A reference cohort of healthy subjects showed no significant changes over the course of a 6-month observa-
tion period (n = 6). (E) The maximum change in ventricle volume of the healthy subjects was ± 6%. (F) The MS patient cohort showed significantly greater 
variability in ventricle volumes (as indicated by the coefficient of variation) compared with healthy controls (**P = 0.0065, Student’s t test).
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and cerebellar regions. Impaired CSF clearance was reported in EAE (43) and could impact VV changes. 
Leptomeningeal inflammation is frequently observed in MS and other neuroinflammatory conditions (44, 
45). Impairment of  CSF elimination associated with meningeal inflammation could contribute to transient 
VV changes in MS. Support for this notion comes from a recent study using the positron-emission tomogra-
phy tracer 11C-PiB, which showed reduced CSF clearance in MS patients compared with healthy controls (46).
Inflammatory processes could interfere with the normal function of  the choroid plexus, leading to 
altered CSF composition or CSF hypersecretion. Inflammation and disruption of  the choroid plexus tissue 
architecture is seen in MS (47, 48), and there is compelling evidence that the choroid plexus is implicated 
in the very early stages of  neuroinflammation. The choroid plexus mediates physiological immune surveil-
lance of  the CNS by entry of  immune cells into the CSF circulation (1), and it is also a site for entry of  
pathological Th17 cells in EAE (49). We previously detected accumulation of  very small superparamag-
netic iron oxide particles (VSOP) in the choroid plexus (50) by MRI, confirmed by histology. Importantly, 
VSOP could be detected in the choroid plexus before the onset of  clinical EAE signs and before the detec-
tion of  histopathology in the rest of  the brain, indicating early involvement of  the choroid plexus in the dis-
ease process (51). Furthermore, in our previous study first demonstrating VV changes in EAE, we showed 
an alteration in the T2 relaxation of  the CSF, suggesting an increase in the free water fraction (15), possibly 
as a result of  altered composition or increased production of  CSF due to choroid plexus inflammation.
Insights into the mechanisms of  how inflammation can disrupt choroid plexus function have come from 
recent studies on experimental models of  posthemorrhagic hydrocephalus (PHH) (52, 53). While PHH was 
previously attributed to primary impairments in CSF reabsorption, these recent studies demonstrate the 
Figure 7. MS patients show variable ventricle volume (VV) changes. Individual MS patients showed considerable variability in the patterns of VV 
changes during the course of 13 monthly MRI examinations. Ventricle volumes from each patient and healthy subject are shown along the x axis; each dot 
represents 1 time point. Results are depicted as a percentage change from the baseline measurement. The vertical lollipop lines indicate the maximum 
contraction observed for each individual during the study period, in percentage change. The dotted line illustrates the maximum ventricle contraction 
observed in the healthy cohort: 6%. Based on this threshold, the cohort was divided into MS patients with contractions > 6% (orange) and MS patients 
without contractions (green). Healthy subjects are depicted in blue.
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contribution of  CSF hypersecretion to the pathogenesis of  PHH. In a model of  intraventricular hemorrhage, 
PHH was shown to be the result of  CSF hypersecretion by the choroid plexus. This was driven by a TLR4- 
and NF-κB–dependent production of  proinflammatory cytokines that, in turn, upregulate Ste20-type stress 
Figure 8. MS patients with contracting ventricles have lower disease severity and duration. (A and B) MS patients who showed contractions (n = 24) in ventricle 
volumes greater than 6% had significantly lower disease severity at the study baseline, as indicated by the Expanded Disability Status Scale, EDSS) (**P = 0.0221, 
Mann-Whitney test) (A), and significantly lower median EDSS during the study period (**P = 0.0063, Mann-Whitney test) (B). (C) The patients with ventricle 
contractions also had significantly shorter total disease duration (***P = 0.046, Student’s t test). (D–F) There were no significant differences between contracting 
and noncontracting patients (n = 9) in volume of CEL (D), T2 (E), or BH lesions (F) over the course of the study.
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kinase (SPAK); this kinase activates ion transporters in the choroid epithelium to increase CSF produc-
tion (52). This could be reversed with drugs targeting these signaling pathways, leading to protection from 
the experimentally induced ventricle enlargement (52). Another group used a small molecule inhibitor of  
SPAK-dependent phosphorylation of  ion transporters and were able to reverse CSF hypersecretion in exper-
imental ischemic stroke (53). These studies demonstrate how inflammatory processes at the choroid plexus 
can result in expansion of  the cerebral ventricles due to CSF overproduction in PHH and have implications 
beyond hydrocephalus and stroke to other acute and chronic inflammatory diseases (54).
Variations in VV and BV are known to be dependent on circadian rhythm (55) and hydration status 
(56–59). Interestingly, the activity of  the glymphatic system is greatly increased during sleep. In the current 
study, we can exclude circadian rhythm and dehydration as contributing factors, since all patients were 
scanned consistently early in the morning and were instructed to eat normally and drink sufficiently. Never-
theless, potential effects of  other physiological processes on VV cannot be entirely excluded. All patients in 
the study were treated with atorvastatin, and some also with IFN-β; therefore, potential confounding drug 
effects on VV cannot be excluded. Patients who experienced acute relapses were also treated with cortico-
steroids, and while the MRI and clinical measures in those patients were postponed by 4 weeks to avoid 
confounding effects on GBCA enhancement, potential effects of  steroids on VV, though unlikely, cannot be 
entirely excluded. In addition to biological variation, differences in slice position between scans and other 
technical sources of  variation often cannot be completely controlled (26, 60). Nevertheless, no significant 
differences between VV contracting and noncontracting patients were observed in terms of  age, sex, the 
proportion also receiving IFN-β therapy, and number of  acute relapses during the study period.
During the initial EAE disease peak, the VV increase was pronounced — up to double the original 
size in some animals. Regardless of  the extent of  the VV changes, all VV returned to normal values upon 
remission of  clinical signs. We detected evidence of  neurodegeneration with FJ staining, which was con-
sistently associated with inflammatory lesions, particularly in the cerebellum and brainstem. Nevertheless, 
the magnitude of  the FJ staining at this early time point was modest, consistent with other reports showing 
mild FJ staining at similar time points in the C57BL/6J MOG EAE model (61). Together with the fact that 
the VV expansion occurred at such an early phase in the disease and was reversible, even toward the end of  
the study when mice still showed clinical signs of  neurological disease, it is highly unlikely that the initial 
VV changes were a consequence of  profound neurodegeneration. Rather, it is more likely that the early VV 
changes were the result of  fluid dysregulation associated with inflammatory processes at this phase of  the 
disease. In contrast, neurodegenerative damage in EAE accumulates progressively over time (62).
The VV changes in the MS patients were less severe than in the EAE animals. A minority of  patients (5 
of  33) in our cohort showed increases in VV in the study period, with no contractions; indeed, this minority 
was responsible for the significant increase in VV seen at the whole group level. This is in line with conven-
tional expectations that VV of MS patients should steadily increase over time — notwithstanding normal 
physiological fluctuations (30). The fact that a majority of  patients we analyzed showed VV contractions, 
as well as expansions, beyond the range of  variation of  healthy subjects suggests that other processes are at 
work, in addition to neurodegeneration. Stratifying the MS cohort based on the plus or minus 6% threshold 
of  normal monthly variance in VV (25) revealed that the patients with contracting ventricles appeared to 
be at an earlier stage of  their disease. If  transient VV fluctuations are associated with acute inflammatory 
activity, then it stands to reason that these fluctuations would be more prominent in RRMS, when inflamma-
tory processes dominate, than SPMS — when acute inflammation is less prominent and neurodegenerative 
processes dominate. This is in line with a previous study that reported that, while PPMS and SPMS patients 
had larger VV at baseline, RRMS patients showed the greatest VV changes over 6 months (63). However, that 
study was not designed to detect month-to-month changes in VV during the study period; therefore, it might 
Figure 9. Time-series analysis of ventricle volume changes in MS. (A) For each individual patient with ventricle volume contractions > 6% (n = 24), we 
calculated the cross-correlation function (CCF) between the time series of ventricle volume (as the X variable) and the time series of the other 8 MRI and 
4 clinical measures (as the Y variables). The CCF yielded 25 significant cross-correlation coefficients, within a time lag of ± 2 months, after FDR correction 
for multiple comparisons. The significant coefficients are depicted as lollipops in the 3D plot; color is scaled to the magnitude of the coefficient. Individual 
patients are arranged on the x axis; the MRI and clinical parameters are arranged on the y axis. The absolute values of the time lags are shown on the z 
axis, and size of the lollipop is scaled to the time lag (lag 0, largest). (B) Using the time series of CEL volume as the X variable and the other MRI and clinical 
parameters (including ventricle volume) as the Y variables, the CCF analysis yielded 23 significant cross-correlation coefficients after correction for multiple 
comparisons. Of these, 9 of 23 were correlations between CEL volume and CEL count at 0 time lags. (C) Repeating the analysis using the time series of 
performance in the 9-hole peg test as the X variable yielded 5 significant cross correlation coefficients after correction for multiple comparisons. 
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have underestimated the relevance of  VV expansions and contractions. Interestingly, that study also showed 
that PPMS patients had the largest VV at the start of  the observation period (63), which might suggest that 
neurodegenerative processes played a larger role in their disease, right from the onset. These speculations will 
require careful study of  PPMS and SPMS patients, with serial MRI.
The clinical study that was the source of  our MS patient data was designed as a time series with month-
ly MRI scans, including multiple parameters such as GBCA enhancement. This permits the use of  time-se-
ries analysis in order to look for correlations between the timing of  changes across multiple parameters — 
an approach that is under-used in MS research. The data set we examined can be considered as a short-time 
series (64), and given that the measurements took place over 1 year, there is no expectation of  seasonality in 
the data, which can be a confounding feature of  time series that extend over several years. Considering the 
short duration and the modest sample size, we adopted a conservative approach to the time-series analysis, 
with no attempt to draw causal interpretations or forecast outcomes. Rather, the objective was to determine 
whether there was any evidence indicating that changes in VV occurred at the same time (or shifted in time) 
as changes in the other MRI and clinical parameters measured.
The time-series analysis detected several significant cross-correlation coefficients distributed among 
the other MRI and clinical parameters. This revealed a complex picture, in which the timing of  VV 
changes in some patients was significantly correlated with the timing of  changes in other parameters. 
This suggests that VV changes may reflect disease activity, although no single parameter dominated the 
set of  significant coefficients. We repeated the time-series analysis using CEL volume — the gold stan-
dard for MS disease activity — to see how the timing of  changes in this parameter compared with the 
other parameters (including VV). There was a high degree of  cross-correlation between CEL volume and 
CEL count at time lag 0, meaning that changes in CEL volume occurred at the same time as changes in 
CEL count, in some though not all patients. Aside from this expected cross-correlation, lesser significant 
coefficients were observed, and these too were distributed among all other parameters. This suggests that 
the degree to which the timing of  changes in VV and CEL volume reflect changes in other disease-related 
parameters was comparable. In contrast, when the analysis was done to compare the timing of  changes 
in performance in the HPT with other disease-related parameters, only 5 significant cross-correlation 
coefficients were retained after correction for multiple comparisons. This could reflect that the HPT mea-
sures motoric performance and may be related to spinal cord involvement (65, 66) or may simply be less 
indicative of  rapid changes when compared with parameters such as VV and CEL volume.
The diagnostic value of  GBCA for revealing disease activity in MS is indisputable. Nevertheless, there 
have recently been increasing safety concerns regarding the potential for long-term deposition of  GBCA 
in the brain (9–12). In light of  these concerns, there is a strong motivation to find contrast-free quantitative 
MRI parameters, which can serve as markers of  disease activity. In this line, quantitative MRI measures 
such as T1 mapping, especially at ultra-high magnetic field strengths, can be especially informative (67). 
In the current study, we used T1 mapping of  EAE brains to quantify gadolinium leakage as an indicator 
of  BBB disruption. Crucially, we could show that the timing of  VV changes coincided with the peak of  
BBB leakage and that both of  these significantly preceded the onset of  clinical signs of  EAE. The T1 maps 
showed a pattern of  contrast enhancement typical for SJL mice, with extensive involvement of  the cere-
bellum, meninges and periventricular regions. This corresponded to histological detection of  immune infil-
trates and gliosis in these locations, and the severity of  the histopathology correlated with the magnitude of  
VV changes. Thus, VV changes may be considered as a surrogate indicator of  inflammatory activity. Future 
studies using even more sensitive histological methods for detecting BBB disruption would add further 
detail, complementing the quantitative T1-mapping approach.
In summary, close monitoring of  VV changes in individual MS patients will be important to understand 
whether these are truly transient or persistent. Persistent changes would indicate irreversible progressive 
destruction, while transient events might be related to other pathological mechanisms superimposed upon 
the neurodegenerative process. Being able to disentangle these intermingled processes will have profound 
implications for determining more effective treatment strategies. Given that the RRMS patients with con-
tracting VV in the current study appeared to be at an earlier phase of  their disease, it is tempting to speculate 
that the cessation of  VV volatility may be an indication of  transition to the progressive phase of  disease. 
This hypothesis remains to be confirmed in larger-scale data sets. Nevertheless, changes in VV could serve 
as a quantitative MRI biomarker of  disease activity, which can be readily acquired in the course of  routine 
clinical investigations of  MS patients. However, in order for this to become part of  routine clinical practice, 
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it will be necessary to have tools available for the clinician to quickly and seamlessly integrate the calculation 
of  VV into the clinical workflow. Continuing advances in machine learning–based methods for analysis of  
MRIs will be crucial for these developments. To accompany VV monitoring, further technical developments 
in MRI-based methods to monitor CSF flow (68) and composition (69) — as well as inflammatory processes 
(70) — are becoming increasingly available, particularly at higher magnetic field strengths. Together, these 
tools can help drive our understanding of  the dynamic changes in the CSF compartment during neuroin-
flammatory disease and can lead to superior diagnosis, prognosis, and monitoring of  patients.
Methods
Induction of  EAE. EAE was induced as previously described (15). Female SJL/J mice (8–12 weeks) were 
obtained from Janvier SAS. A total of  n = 35 mice in 6 cohorts were used in the study. Mice were immu-
nized s.c. with 250 μg PLP139–151 (Pepceuticals Ltd.) and 800 μg mycobacterium tuberculosis H37Ra (Dif-
co), and they were administered 200 ng of  pertussis toxin (List Biological Laboratories) on d0 and d2. Mice 
were weighed and scored daily as follows: 0, no disease; 1, tail weakness and righting reflex weakness; 2, 
paraparesis; 3, paraplegia; 4, paraplegia with forelimb weakness or paralysis; and 5, moribund or dead.
Animal MRI. Animals were anesthetized with a mixture of  1%–1.5% isofluorane (Abbott GmbH & 
Co.), air, and oxygen, and they were placed on an animal holder, kept warm with circulating water. Body 
temperature and respiration rate were monitored continuously with a remote monitoring system (Model 
1025, SA Instruments Inc.). MRI was performed (Supplemental Methods), keeping slice positioning con-
stant through the experiment, positioned parallel to the base of  the brain. Mice were imaged at baseline, 
2 days before immunization, and every 2–3 days after immunization, until day 64 after EAE induction. A 
total of  n = 9 mice underwent the full longitudinal examination. We confirmed that the signal-to-noise and 
contrast-to-noise ratio (between cortex and ventricles) were consistent throughout the entire study period.
Analysis of  MRI data. Quantification of  mouse brain VV was done as in our previous study (15), using 
FMRIB Software Library (FSL v5.0, www.fmrib.ox.ac.uk/fsl) (71–73), and the transformed ventricle 
masks were manually corrected (Supplemental Methods). Data from the T1 maps were extracted and post-
processed using MATLAB (MathWorks Inc.), MATLAB Image J software module (MIJ), and Advanced 
Normalization Tools Toolkit (74, 75) (Supplemental Methods).
Histology. Brain tissue was collected from n = 19 mice at various time points: baseline (unimmunized 
controls) and d3, d5, d8, and d11 p.i. After terminal anesthesia using ketamine/xylazine, mice were perfused 
transcardially with 20 mL PBS and then with 20 mL zinc fixative (0.5% zinc acetate, 0.5% zinc chloride, 
0.05% calcium acetate) (Sigma-Aldrich). Following extraction, brains were postfixed, frozen in OCT, and cut 
into 15 μm cryosections. Sections were stained with H&E according to standard procedures. H&E-stained 
tissue sections were reviewed and scored for the presence of  inflammation in the following regions: menin-
ges, periventricular regions, brainstem, cerebellum, cortex, and hippocampus. Absence of  inflammation was 
scored as 0; minor signs of  inflammation as +; multiple inflammatory foci as ++; and severe inflammation 
as +++. These semiquantitative scores were then correlated with the VVs and ΔT1 values. Immunostaining 
protocols (Supplemental Methods) were also performed.
Healthy human controls. Data from healthy control subjects were obtained from 2 publications that per-
formed repeated serial MRI scans on healthy individuals and which had made their raw data available to 
the scientific community (25, 26). In one study to investigate intraindividual variability in brain structures 
and other measurements, subjects (n = 6) underwent multiple serial MRI scans over 6 months. From this 
data set, we selected scans at 1-month intervals in order to match the timing of  the scans in the MS patient 
cohort. Demographic details of  these subjects are listed in Supplemental Table 1. In a separate study to eval-
uate intra- and intersession reliability of  brain imaging and automated segmentation software, n = 3 subjects 
underwent repeated MRI scans within a 31-day period (26). Given the retrospective nature of  our study, it was 
not possible to age-match the healthy controls with the MS patient cohort. Both studies acquired T1-weighted 
scans, using 3.0 Tesla clinical MR scanners; details about the scan parameters can be found in the original 
publications (25, 26). Absolute VVs from scans of  healthy controls were obtained using FreeSurfer v5.3 (76).
MS Patient cohort. Data from RRMS patients were obtained from our previous clinical study inves-
tigating oral atorvastatin therapy (NCT00616187) (24). All patients (n = 33) in this study had clinically 
definite MS (77) and had at least 1 CEL on brain MRI at the time of  enrolment. Clinically active disease 
(i.e., signs of  relapse) was not required for inclusion in the study. In addition to treatment with atorvas-
tatin, 10 of  33 patients were cotreated with IFN-β. Patients who experienced acute relapses underwent 
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corticosteroid treatment (methylprednisolone) for 3–5 days; subsequent MRI and clinical examination 
was postponed by 4 weeks to avoid confounding effects. Patients underwent 13 MRI examinations at 
1-month intervals over the course of  1 year. T1- and T2-weighted MRI scans were acquired using a 1.5 
Tesla clinical MR scanner (Siemens Sonata, Siemens Medical Systems). Diffusion-weighted imaging 
was performed, and the apparent diffusion coefficient (ADC) calculated in 4 regions of  interest: corpus 
callosum (ADC CC), basal ganglia (ADC BG), brainstem (ADC BS), and normal-appearing white 
matter (ADC WM). All scans were performed between 8 and 9 a.m. in order to avoid circadian bias, 
and patients were advised to have regular meals and drinks to avoid dehydration. Detailed information 
on the scan parameters can be found in the original publication (24). Demographic and clinical details 
from the original publication are listed in Supplemental Table 1 (note that the current study used 33 
patients who completed the full MRI scan protocol at all time points).
Analysis of  MRI Data (Supplemental Methods) included VV and BV, CEL numbers and volumes, 
T2-weighted lesions and BH lesions. Additional parameters included the Paced Auditory Serial Addition 
Test (PASAT), the 9-hole peg test of  the dominant (hpt dom) and nondominant (hpt ndom) hand, and the 
timed walk test (twt). EDSS scores were assessed at baseline and at selected time points during the study.
Statistics. For each patient, VVs, as well as lesion volumes, lesion counts, and additional clinical 
measures that were gathered and quantified from the 12-month clinical study, were analyzed using 
time-series analysis. The CCF calculates the cross-correlation coefficient, which indicates the relation-
ship between 2 metrics as they change over time. Significant coefficients indicate that events of  1 series 
precede (negative time lag) or follow (positive time lag) the events of  another series. Absence of  sig-
nificant CCF coefficients indicates that no temporal relationship between the 2 series exists. For this 
12-month clinical study, we adopted a conservative approach, considering only those coefficients that 
were significant at time lags between –2 to +2 months. Given that the CCF requires continuous data, 
noncontinuous ordinal variables such as EDSS were not included in the time-series analysis. All time 
series for each individual patient for each parameter were detrended by first-order differencing, in which 
each point is replaced by the difference between its value and the value of  the preceding point. This 
was done to ensure that the time series were stationary — i.e., lack an overall trend — in order to avoid 
spurious false-positive cross-correlations. The differencing was done using the R package forecast (78). 
Following first-order differencing, we confirmed stationarity for all time series for all patients with the 
Augmented Dickey-Fuller test (79), using the R package fUnitRoots (80).
The CCF was then applied using the R package time series (81) to look for temporal relationships 
between the VV time series and the time series for the other parameters for each individual patient. The 
Benjamini-Hochberg FDR method was used to correct for multiple comparisons, with FDR-corrected 
P < 0.05 considered significant. We also verified that there was no autocorrelation (periodicity) in the 
time series of  each parameter we studied, using the ACF function (R package, time series).
Statistical analysis (including those in Supplemental Methods) was done using the statistical comput-
ing environment R v.3.3.4 (https://www.R-project.org) and GraphPad Prism v.5.01 (GraphPad Software, 
Inc.). All statistical tests are specified throughout the mansucript.
Study approval. Animal experiments were carried out in accordance with the guidelines approved by 
the Animal Welfare Department of  the LAGeSo State Office of  Health and Social Affairs in Berlin and 
in accordance with international guidelines on the reduction of  discomfort (86/609/EEC). All procedures 
performed in studies involving human participants were in accordance with the ethical standards of  the 
institutional and/or national research committee (Charité, German Federal Institute for Drugs and Med-
ical Devices, BfArM) and with the 1964 Helsinki declaration and its later amendments. Written informed 
consent was received from participants before inclusion in the study.
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